Holen Sie sich die Stockscreener-App
114.83
9.70%
10.15
Handel nachbörslich:
114.83
Schlusskurs vom Vortag:
$104.68
Offen:
$111.4
24-Stunden-Volumen:
2.65M
Relative Volume:
3.00
Marktkapitalisierung:
$23.62B
Einnahmen:
$2.98B
Nettoeinkommen (Verlust:
$-717.57M
KGV:
-38.29
EPS:
-2.9987
Netto-Cashflow:
$-264.74M
1W Leistung:
+16.88%
1M Leistung:
+20.39%
6M Leistung:
+3.47%
1J Leistung:
+29.77%
1-Tages-Spanne:
$111.26
$120.32
1-Wochen-Bereich:
$96.54
$120.32
52-Wochen-Spanne:
$76.53
$131.49
Biontech Se Adr Stock (BNTX) Company Profile
Vergleichen Sie BNTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
114.83 | 23.62B | 2.98B | -717.57M | -264.74M | -2.9987 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.42 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.85 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.65 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.97 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.13 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2025-01-10 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-11-19 | Eingeleitet | Berenberg | Buy |
| 2024-11-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-08 | Hochstufung | Goldman | Neutral → Buy |
| 2024-09-24 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-08-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-08-02 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-14 | Eingeleitet | Evercore ISI | In-line |
| 2024-02-23 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-01-05 | Eingeleitet | Oppenheimer | Perform |
| 2023-12-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-10-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-17 | Hochstufung | Redburn | Neutral → Buy |
| 2022-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-17 | Eingeleitet | Cowen | Market Perform |
| 2022-07-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2021-12-16 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Hold |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-08-11 | Hochstufung | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-06-16 | Herabstufung | Redburn | Neutral → Sell |
| 2021-05-18 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-08-03 | Fortgesetzt | Berenberg | Buy |
| 2020-07-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-30 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-03-09 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-01-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-11-05 | Eingeleitet | Wolfe Research | Outperform |
| 2019-11-04 | Eingeleitet | Berenberg | Buy |
| 2019-11-04 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-11-04 | Eingeleitet | JP Morgan | Overweight |
| 2019-11-04 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-04 | Eingeleitet | UBS | Buy |
Alle ansehen
Biontech Se Adr Aktie (BNTX) Neueste Nachrichten
Stocks With Rising Relative Strength: BioNTech ADR - Investor's Business Daily
BioNTech, Pfizer report good news from vaccine trial - Morningstar
Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength? - Yahoo Finance
Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last? - Yahoo Finance
CureVac’s amended patent upheld by European Patent Office - Investing.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
BioNTech’s Earnings Call: Oncology Growth Amidst Challenges - TipRanks
BioNTech’s 2024 Earnings Highlight Oncology Focus - TipRanks
BioNTech Earnings: 2025 Guidance Disappoints, Fair Value Lowered - Morningstar
BioNTech's mRNA Technology and Acquired Oncology Programs Could Support a Future Moat - Morningstar
Jefferies maintains BioNTech stock Buy rating, $149 target - Investing.com India
BioNTech Q4 earnings beat, but stock falls 3% on weak 2025 outlook - Investing.com
Earnings call transcript: BioNTech beats Q4 2024 expectations, stock dips - Investing.com
BioNTech Surpasses Q4 Revenue Estimates - The Motley Fool
US Stocks Likely To Open Lower After Trump Hints At Looming Recession: Expert Says Can't Rule Out A Bear Market As Indices Inch Towards Correction Territory - Benzinga
BioNTech reports Q4 EPS EUR 1.08 vs. EUR 1.88 last year - TipRanks
Here's Why Moderna Stock Soared 16% On Wednesday - Barchart
Here's Why Moderna Stock Soared 16% on Wednesday - Yahoo Finance
BioNTech SE's RNA-based vaccine for malaria placed on clinical hold by FDA - MSN
Paramount Group Inc (PGRE) Shares Soar Above 1-Year High - The News Heater
Pfizer and BioNTech violated COVID-19 vaccine patent held by Moderna, German court rules - The Globe and Mail
BioNTech stock falls after FDA clinical hold on malaria vaccine trial - Investing.com
BioNTech SEADR to Host Earnings Call - ACCESS Newswire
Vaccine Stocks Rise as Chinese Scientists Discover a New Coronavirus - Yahoo Finance
AASTOCKS Financial NewsBioNTech SE (BNTX) - AASTOCKS.com
Are Medical Stocks Lagging Auna S.A. (AUNA) This Year? - MSN
What Makes BioNTech (BNTX) a New Buy Stock - Yahoo Finance UK
BioNTech SE ADR (BNTX) did well last session? - US Post News
Electronic Arts Posts Upbeat Earnings, Joins Mattel, Johnson Controls, Mueller Water Products And Other Big Stocks Moving Higher On WednesdayBloom Energy (NYSE:BE), BigBear.ai Hldgs (NYSE:BBAI) - Benzinga
Pfizer's Q4 Earnings Beat Estimates, Non-Covid Drugs Drive Sales - Barchart
Moderna and BioNTech shares fall after Senate committee vote on RFK Jr. - Investing.com
Hesai Group ADR (HSAI) shows promising results - US Post News
Will Non-COVID Drugs Drive PFE's Top Line in Q4 Earnings? - Yahoo Finance
Will Non-COVID Drugs Drive PFE's Top Line In Q4 Earnings? - Barchart.com
Validea Benjamin Graham Strategy Daily Upgrade Report1/31/2025 - Nasdaq
BioNTech's SWOT analysis: oncology pipeline, cash boost stock outlook - Investing.com
Stocks To Watch: BioNTech ADR Sees Relative Strength Rating Rise To 84 - Investor's Business Daily
Wall Street Analysts Predict a 25.59% Upside in BioNTech (BNTX): Here's What You Should Know - MSN
Years-Old List of Alleged Pfizer COVID-19 Vaccine 'Side Effects' Is Misleading - Snopes.com
Fact Check: Years-Old List of Alleged Pfizer COVID-19 Vaccine 'Side Effects' Is Misleading - Yahoo
BioNTech Expands Cancer Drug Pipeline: Launches Key Lung Cancer Trials, Advances Immunotherapy Programs - StockTitan
Why BioNTech (BNTX) Shares Are Volatile TodayBioNTech (NASDAQ:BNTX) - Benzinga
BioNTech SE ADR falls Wednesday, underperforms market - MarketWatch
Vaccine Stocks Jump After CDC Reports First US Bird-Flu Death - Yahoo Finance
BioNTech SE ADR rises Tuesday, outperforms market - MarketWatch
Finanzdaten der Biontech Se Adr-Aktie (BNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.44%
2.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):